Mutual Funds & ETF's
Treasury & Bonds
View Full List
Dow Jones Industrial Average
Standard & Poors 500
NYSE COMPOSITE INDX
Bristol’s bad news is good for rivals: analysts
Posted on August 02, 2012 at 17:51 PM EDT
Bristol-Myers Squibb’s hepatitis C drug INX-189 might be a dud, but that may be a boon for rival drug developers, analysts say.
Read More >>
Achillion Pharmaceuticals, Inc.
Bristol-Myers Squibb Co.
Gilead Sciences, Inc.
Idenix Pharmaceuticals, Inc.
Johnson & Johnson
Merck & Co., Inc.
Vertex Pharmaceuticals, Inc.
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Terms and Conditions
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Bots go here